EXICURE, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- EXICURE, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $500.00K.
- EXICURE, INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $1.60M.
- EXICURE, INC. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $4.60M.
- EXICURE, INC. stock issued during period, value, new issues for the quarter ending 2022-06-30 was $4.89M.
- EXICURE, INC. stock issued during period, value, new issues for fiscal 2025 was $1.60M, a 87.10% decline from fiscal 2024.
- EXICURE, INC. stock issued during period, value, new issues for fiscal 2024 was $12.40M, a 169.78% increase from fiscal 2023.
- EXICURE, INC. stock issued during period, value, new issues for fiscal 2023 was $4.60M, a 6.18% decline from fiscal 2022.
- EXICURE, INC. stock issued during period, value, new issues for fiscal 2022 was $4.90M, a 52.12% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $1.60M 10-K · filed 2026-03-25 | |
| 2025-09-30 | $500.00K 10-Q · filed 2025-11-07 | |
| 2025-03-31 | $1.60M 10-Q · filed 2026-08-14 | |
| 2024-12-31 | $12.40M 10-K · filed 2026-03-25 | |
| 2023-12-31 | $4.60M 10-K · filed 2025-03-18 | |
| 2023-03-31 | $4.60M 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $4.90M 10-K · filed 2024-06-06 | |
| 2022-06-30 | $4.89M 10-Q/A · filed 2024-06-06 | |
| 2021-12-31 | $10.23M 10-K · filed 2023-03-27 | |
| 2020-12-31 | $2.77M 10-K · filed 2022-03-25 | |
| 2020-03-31 | $2.77M 10-Q · filed 2021-11-19 | |
| 2019-09-30 | $58.87M 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $20.07M 10-K · filed 2020-03-10 |
| 2018-09-30 | $20.07M 10-Q · filed 2019-11-07 | $30.52M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | |
| 2018-03-31 | $436.00K 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $10.01M derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-09-23 | $27.06M 10-K/A · filed 2019-09-23 |
| 2016-12-31 | $444.00K 10-K · filed 2018-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |